Mar 5, 2026 08:00AM
Feb 26, 2026 04:49AM
Feb 25, 2026 04:01PM
Feb 5, 2026 08:52AM
Feb 5, 2026 08:51AM
Feb 5, 2026 08:01AM
Feb 5, 2026 08:00AM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Jan 26, 2026 08:00AM
Jan 26, 2026 08:00AM
Jan 12, 2026 08:31AM
Jan 12, 2026 08:30AM
Dec 19, 2025 04:08PM
Dec 19, 2025 09:06AM
Dec 9, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Mirum Pharmaceuticals (MIRM)
Dec 8, 2025 03:01PM
Dec 8, 2025 08:00AM
Dec 8, 2025 08:00AM
Nov 25, 2025 04:02PM
Nov 10, 2025 08:00PM
Nov 7, 2025 08:11AM
Nov 7, 2025 08:10AM Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
Nov 4, 2025 04:01PM
Nov 3, 2025 04:05PM
Oct 28, 2025 04:02PM
Oct 10, 2025 07:45PM
Sep 10, 2025 06:45PM
Sep 8, 2025 08:00AM
Aug 27, 2025 04:02PM Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Aug 7, 2025 04:17AM
Aug 6, 2025 04:01PM
Jul 31, 2025 07:00AM
Jul 30, 2025 04:01PM
Jul 10, 2025 06:15PM
Jun 10, 2025 08:40PM
May 19, 2025 08:52AM Mirum Pharmaceuticals, Inc. (MIRM) appoints Doug Sheehy as CLO
May 19, 2025 08:30AM
May 14, 2025 04:05PM
May 9, 2025 06:00PM
May 9, 2025 08:30AM
May 9, 2025 04:40AM
May 7, 2025 04:01PM
Apr 30, 2025 08:30AM Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
Apr 28, 2025 08:30AM
Apr 14, 2025 08:32AM
Apr 14, 2025 08:30AM
Apr 10, 2025 07:00PM
Mar 27, 2025 08:33AM
Mar 27, 2025 08:30AM
Mar 10, 2025 08:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2025 07:12AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All